


ABSTRACT

A compound represented by the general formula (I) of the present invention, which has an EP₁ receptor antagonism:

5 [Chem.]



[wherein A represents a benzene ring or the like; Y represents a C₁₋₆ alkylene group or the like; R^N represents a hydrogen atom or a C₁₋₆ alkyl group; R¹ represents a hydrogen atom, a C₁₋₆ alkyl group or the like; R² represents a phenyl group which may have a substituent, a 5-membered aromatic heterocyclic group which may have a substituent, a 6-membered aromatic heterocyclic group which may have a substituent or the like; R³ represents a halogen atom, a C₁₋₆ alkoxy group or the like; R⁴ represents a hydrogen atom or the like; and R⁵ represents a hydrogen atom or the like] or a pharmaceutically acceptable salt thereof is provided. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.

20